A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

Overview

About this study

The purpose of this study is to evaluate total opioid consumption during the first 7 postoperative days.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (≥18 years) undergoing elective outpatient facial plastic surgery.

  • Able to consent and comply with study procedures.

  • Planned postoperative use of suzetrigine per provider discretion.

 

Exclusion Criteria:

  • Age <18.

  • Pregnant or breastfeeding.

  • Women on hormonal birth control who decline suzetrigine-related counseling.

  • Patients using strong CYP3A4 inhibitor medications (i.e. itraconazole, ketoconazole, clarithromycin, ritonavir, and grapefruit juice).

  • Known allergy to suzetrigine.

  • Vulnerable or protected research populations.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/6/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Deanna Menapace, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available
.
CLS-20598357

Mayo Clinic Footer